Skip to main content
AEON Biopharma, Inc. logo

AEON Biopharma, Inc. — Investor Relations & Filings

Ticker · AEON ISIN · US00775E1029 US Manufacturing
Open in API
Filings indexed 317 across all filing types
Latest filing 2023-05-09 Proxy Solicitation & In…
Country US United States of America
Listing US AEON

About AEON Biopharma, Inc.

https://www.aeonbiopharma.com/

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused exclusively on developing therapeutic applications for botulinum toxins. The company is advancing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for the treatment of debilitating nervous system-related and neuromuscular disorders. Its lead clinical programs are investigating ABP-450 for the prevention of chronic and episodic migraines and the treatment of cervical dystonia. By concentrating solely on therapeutic indications, AEON aims to unlock the full potential of neurotoxins to provide lasting relief for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
S-4/A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an Amendment No. 4 to Form S-4 filed with the SEC, which is a registration statement under the Securities Act of 1933. It includes a detailed proxy statement/prospectus related to a business combination (merger) involving Priveterra Acquisition Corp. and AEON Biopharma, Inc. The text includes notice of a special meeting of stockholders to vote on the business combination and related proposals such as charter amendments, stock issuance, director elections, and incentive plans. The document is primarily a proxy solicitation and information statement to shareholders to provide information and request votes for the special meeting. It is not a financial report, earnings release, or audit report. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length is substantial and contains detailed proposals and annex references typical of proxy statements.
2023-05-09 English
Regulatory Filings 2023
Regulatory Filings
2023-05-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Priveterra Acquisition Corp. It details an amendment to a Business Combination Agreement and related Sponsor Support Agreement, promissory note issuance, and other merger-related updates. It references the upcoming S-4 Registration Statement and proxy materials for a stockholder vote on the merger. The content focuses on merger transaction updates and agreements rather than full financial statements or earnings data. It is not an earnings release, annual or interim report, or proxy solicitation itself, but a current report disclosing material definitive agreements and amendments related to a merger. Therefore, the filing type corresponds to a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other more specific categories like M&A filings (which are typically Forms 425, DEFM14A, etc.) or merger proxy statements themselves.
2023-05-01 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-4 Amendment No. 2 filed by Priveterra Acquisition Corp. It discusses accounting treatment and disclosures related to deferred underwriting fees and references amendments to the Registration Statement and a Form 10-K amendment. The document is a correspondence letter addressing regulatory comments and amendments to filings, not the filings themselves. It is not a full financial report, earnings release, or other report type but rather a regulatory correspondence. The document length is under 5,000 characters and it is a response letter to SEC comments, fitting the category of Regulatory Filings (RNS).
2023-05-01 English
FORM S-4/A
Merger & Acquisition Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, which includes a proxy statement and prospectus related to a business combination (merger) between Priveterra Acquisition Corp. and AEON Biopharma, Inc. It contains detailed information about the merger agreement, the special meeting of stockholders to approve the transaction, and related proposals. The content focuses on merger terms, shareholder voting, and transaction details rather than financial results or earnings. This type of filing is specifically related to merger and acquisition activity and tender offers. Therefore, the appropriate classification is 'Merger & Acquisition' (MA). The document length and detail confirm it is the actual filing, not just an announcement or summary.
2023-05-01 English
425 Filing
Regulatory Filings
2023-05-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.